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CORONAVIRUS 
DISEASE 2019 
(COVID-19) 
Matthew Dunbar, Pharm.D. Candidate 2020 
Ohio Northern University 
NOTHING 
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§  Discuss epidemiology of SARS-CoV-2 and its relation to other coronaviruses 
§  Discuss route of transmission, period of infectivity, and possible immunity  
§  Review risk factors associated with severe illness and available methods for 
predicting mortality 
§  Review clinical presentation including symptomology, abnormal labs, and 
image findings 
§  Discuss overall course as well as complications that may develop for those 
infected 
§  Develop an understanding of management of a patient with COVID-19, 
including investigational agents currently being evaluated for use  
§  Coronaviruses are widespread among birds and 
mammals  
§  Bats are host to the largest variety of genotypes 
§  4 serotypes associated with disease in humans 
§  HCoV-229E 
§  HCoV-NL63 
§  HCoV-C43 
§  HCoV-HKU1 
§  Severe Acute Respiratory Syndrome (SARS-CoV) 
§  2002 
§  Middle Eastern Respiratory Syndrome (MERS-CoV) 
§  2012 
Anthony SJ, et al. Virus Evol. 2017;1(3):
012. 
Guant ER. J Clin Microbiol. 2010;48(8):
2940.  
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EPIDEMIOLOG
Y 
CONT. 
§  Coronavirus disease 2019 
(COVID-19) 
§  Betacoronavirus  
§  Closely related to SARS-CoV, hence 
its name SARS-CoV-2 
§  Bats are likely the primary source 
 
§  2 types of SARS-CoV-2 
§  L type 
§  S type 
 
 
Zhou P, et al. Nature. 2020;579(7789:270. 
Zhu N, et al. N Engl J Med. 2020;382(8):
727. 
Tang X, et al. National Science Review. 
2020.  
Thought to occur mainly via 
respiratory droplets 
Can infect another individual if 
virus makes direct contact with 
mucous membranes  
Or if an individual touches an 
infected surface and then 
touches his or her eyes, nose, 
or mouth  
Van Dorelamalen N, et al. N Engl J Med. 
2020. 
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§  Interval is uncertain 
§  Most of the information we have are from 
studies evaluating viral RNA detection 
§  Duration of viral shedding has also been found 
to be variable  
§  In a study of 21 patients with mild illness, 90% had 
repeated negative viral RNA swabs 10 days after 
symptom onset 
§  In another study of 137 patients, median viral 
shedding was 20 days (range of 8-37 days) 
Zou L, et al. N Engl J Med. 2020;382(12):
1177. 
Liu Y, et al. Lancet Infect Dis. 2020. 
Zhou F, et al. Lancet. 2020;395(10229):
1054.  
PERIOD OF 
INFECTIVIT
Y CONT. 
§  Rates of transmission from an individual with a 
symptomatic infection vary by location  
§  China: 1-5% among >38,000 close contacts of 
confirmed COVID-19 patients 
§  United States: 0.45% among 445 close contacts of 
10 confirmed patients  
§  Transmission from asymptomatic individuals is 
still largely unknown  
§  Singapore: 6.4% 
Report of the WHO-China Joint Mission on Coronavirus 
Disease 2019 (COVID-19). 
Burke RM, et al. MMWR Morb Mortal Wkly Rep. 2020;69(9):
245.  
Wei WE, et al. MMWR Morb Mortal Wkly Rep. 2020. 
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§ Antibodies are induced in 
those who have been 
infected  
§ Preliminary evidence 
suggests some of these 
antibodies may be 
protective 
§ Currently unknown how 
long protective immune 
response will last  
 
To KK, et al. Lancet Infect Dis. 2020. 
Zhou F, et al. Lancet. 2020;395(10229):1054.  
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§  Report from Chinese Center for 
Disease Control and Prevention: 
§  Mild: 81%  
§  No or mild pneumonia 
§  Severe: 14% 
§  Dyspnea, hypoxia, or > 50% lung 
involvement on imaging within 
24-48 hours 
§  Critical: 5% 
§  Respiratory failure, shock, 
multiorgan dysfunction 
Wu Z and McGoogan JM, JAMA. 2020 
Italy: 7.2% 
South Korea: 0.9% 
United States: 
1.1%  
Grasselli G, et al. JAMA. 2020. 
KCDC. Updated on COVID-19 in Korea. 2020 Mar 
14.  
CDC. Cases in the US. 2020 Mar 23.  
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§  Severe illness can occur in health 
individuals of any age  
§  Primarily occurs in adults of advancing 
age or those with certain comorbid 
conditions: 
§  Diabetes 
§  Hypertension 
§  Cardiovascular disease 
§  Chronic lung disease 
§  CKD 
§  Cancer 
 
Zhou F, et al. Lancet. 2020;395(10229):1054.  
•  Mean number of comorbidities was 2.7 
•  3 patients had no underlying comorbidities  
355 fatal cases in Italy 
•  Median age was 83 
•  94% had an underlying condition 
•  Hospitalization rate: 55% 
•  Fatality rate: 34% 
Outbreak of COVID-19 in several long-term care facilities in Washington 
Onder G, et al. JAMA. 2020. 
McMichael TM, et al. N Engl J Med. 2020.  
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§  MuLBSTA Score 
 
No Yes 
Multilobe infiltrate 0 5 
Absolute Lymphocyte 
count <0.8x109/L 
0 4 
Bacterial infection 0 4 
Smoking history 0 Prior: 2 3 
Hypertension 0 2 
Age ≥ 60 years 0 2 
Gou L, et al. Front Microbiol. 
2019;10:2752. 
Acute kidney injury  
Lymphopenia 
Elevated liver enzymes 
Elevated PT  
Elevated troponin  
Elevated D-dimer (>1 mcg/mL) 
Zhou F, et al. Lancet. 2020;395(10229):1054.  
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Pneumonia seems to be the most frequent manifestation of infection, characterized by 
fever, cough, and fatigue 
Fever: 99% Fatigue: 70% Dry Cough: 59% 
Anorexia: 
40% 
Myalgias: 
35% 
Dyspnea: 
31% 
Sputum 
production: 
27% 
Study of 138 patients in Wuhan:  
Wang D, et al. JAMA. 2020. 
LAB AND IMAGE 
FINDINGS 
§  Lab findings: 
§  Leukopenia or leukocytosis 
§  Elevated aminotransferase 
§  Elevated lactate dehydrogenase 
§  Normal pro-calcitonin on admission 
§  Imaging: 
§  CT chest showing bilateral ground-
glass opacification  
Wang D, et al. JAMA. 2020. 
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Patients with initially mild 
symptoms may progress over 
the course of a week 
•  Study of 138 patients 
hospitalized in Wuhan: 
•  Dyspnea: 5 days after 
symptom onset 
•  Hospitalization: 7 days 
Acute Respiratory Distress 
Syndrome (ARDS) 
•  Acute hypoxemic respiratory 
failure 
•  Can manifest quickly after 
onset of dyspnea 
•  20% developed ARDS 
•  12.3% required mechanical 
ventilation 
Wang D, et al. JAMA. 2020. 
§  Cardiac injury 
§  Late complication 
§  Arrhythmia 
§  Pericarditis 
§  Pericardial effusion 
§  Cardiomyopathy 
§  Sudden cardiac death 
§  Sepsis, shock, multi-organ failure appear to 
be uncommon  
§  WHO: recovery time is around 2 weeks for 
mild infections and 3-6 weeks for severe  
Wang D, et al. JAMA. 2020. 
World Health Organization. 2020 Feb 24. 
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§  Home care: appropriate for those with mild 
infection 
§  Focuses on isolation and prevention of 
transmission to others 
§  CDC recommendations:  
§  Test-based strategy: 
§  Resolution of fever  
§  Improvement in respiratory 
symptoms 
§  2 consecutive negative 
nasopharyngeal swab specimens 
collected > 24 hours apart 
§  Non-test-based strategy: 
§  ≥ 7 days since symptom onset 
§  ≥ 72 hours since symptom recovery 
CDC. Disposition of non-hospitalized 
patients with COVID-19. 2020 Mar 16.  
§  Hospital care 
§  Supportive care and infection control  
§  WHO recommends standard, contact, and 
droplet precautions with eye and face 
protection 
§  Patients with severe disease often need 
oxygenation 
§  SpO2 ≥ 90% 
§  Use of low-flow oxygen systems via nasal 
cannula (up to 6L/min) 
§  Next steps are controversial and appear to be 
on a case by case basis: 
§  High-flow vs early intubation 
Anesi GL, et al. UpToDate. 2020 Apr 4. 
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MANAGEME
NT CONT. 
Sedation 
and 
analgesia 
GI and VTE 
prophylaxis  
Nutritional 
support 
Glucose 
control  
Anesi GL, et al. UpToDate. 2020 Apr 4. 
•  Proposed mechanisms: 
•  Weak bases that raise pH of 
organelles essential for membrane 
fusion and subsequent release of 
virions 
•  Inhibit entry through glycosylation of 
ACE2 
Demonstrated 
in vitro 
activity 
against SARS-
CoV-2 
Yao X, et al. Clin Infect Dis. 2020.  
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Philippe G, et al. Int J Antimicrob Agents. 2020.  
§  Chloroquine included in treatment guidelines from China’s National Health 
Commission 
§  Reported to be associated with reduced disease progression and duration of symptoms 
§  Possible toxicity 
§  QTc prolongation 
§  Cardiomyopathy 
§  Retinal toxicity 
§  Optimal dosing unknown (hydroxychloroquine): 
§  400 mg BID on day 1, then 400 mg daily for 5 days 
§  400 mg BID on day 1, then 200 mg BID for 5 days 
§  600 mg BID on day 1, then 400 mg daily for 4 days  
§  FDA: 800 mg on day 1, then 400 mg daily for 4-7 days 
Yao X, et al. Clin Infect Dis. 2020.  
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§  Novel nucleotide analogue 
§  Demonstrated in vitro activity against SARS-
CoV-2 
§  Proposed mechanism: 
§  Inhibition of RNA-dependent RNA polymerase  
§  Several clinical trials are ongoing to evaluate 
efficacy 
§  Compassionate use for pregnant women and 
children 
§  IV: 200 mg as a single dose on day 1, then 100 
mg daily for 5-10 days 
Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 
Novel Coronavirus (2019-nCoV). 2020 Jan. 
Agostini ML, et al. mBio. 2018 Mar;9(2).  
§  Protease inhibitor 
§  Primarily used in the treatment of HIV 
§  Found to have no role in treatment  
§  Randomized trial of 199 patients with 
severe disease 
§  No difference in time to clinical 
improvement or mortality at 28 
days 
Cao B, et al. N Engl J Med. 2020.  
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CONVALESCEN
T PLAMSA 
§  Collected from individuals who have 
recovered  
§  May contain antibodies to SARS-CoV-2 
§  Case series in Shenzen, China: 
§  5 patients 
§  Decreased nasopharyngeal viral load 
and improved oxygenation 12 days 
post transfusion 
§  FDA is accepting emergency new drug 
applications for patients with severe 
disease 
Shen C, et al. JAMA. 2020.  
§  Patients who are suspected for COVID-19 infection often present with 
symptoms consistent with viral pneumonia  
§  Progression of mild to severe disease can happen rapidly and is usually 
associated with dyspnea requiring oxygenation therapy 
§  For now, diagnosis and effective triage of patients is based on severity of 
symptoms in addition to abnormal imaging and laboratory findings 
§  Management of those with confirmed or suspected COVID-19 focuses on 
supportive treatment  
§  There are several investigational therapies currently being explored as 
possible antiviral treatment for COVID-19, however their efficacy is still 
unknown 
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